In Focus: Pfizer Inc. EL and ENPH

Earnings Summary Feb 04 2025

Note: We are sharing the synopsis of the earnings, and it is not financial advice. We do not discuss our short recommendations/research in the newsletter. To gain access to Unicus Research’s short ideas, email laks@unicusresearch.com.

Please note that the Unicus Newsletter is for informative purposes only and is not financial advice.

Pfizer Inc.

PFE 0.00%↑ released its 4Q 2024 earnings this morning.

PFE reported Non-GAAP EPS of $0.63, beating by $0.17, and revenue of $17.8B, beating by $540M. We are not recommending PFE as a short for our clients; however, we have been recommending one of its competitors as a short for more than a year—PFE’s competitor is on its way to ZERO.

Here is our summary and insights on $PFE’s 4Q 2024.

Summary:

• PFE reported revenue of of $17.8B (+24.9% Y/Y) beats by $540M.

• Reaffirms All Components of Full-Year 2025 Financial Guidance, including Revenues in a range of $61.0 to $64.0 Billion $63.00B consensus and Adjusted Diluted EPS in a range of $2.80 to $3.00 vs $2.93.

• On Track to Deliver Overall Net Cost Savings of Approximately $4.5 Billion by End of 2025 from Ongoing Cost Realignment Program.